Polarean Imaging
plc
("Polarean" or the "Company")
Notice of
results
Polarean Imaging plc (AIM: POLX), a
commercial-stage medical device leader in advanced Magnetic
Resonance Imaging ("MRI") of lung function, confirms that it
will be announcing its half year results for the six months ended
30 June 2024 on Wednesday, 4 September 2024.
Christopher von Jako, Ph.D., Chief Executive Officer,
and Charles Osborne, Chief Financial Officer, will be hosting a
live online presentation relating to the results via the Investor
Meet Company platform on Wednesday, 4 September 2024 at 17.30
BST.
The presentation is open to all existing and
potential shareholders. Questions can be submitted pre-event via
your IMC dashboard up until 09:00 BST the day before the meeting or
in real time during the presentation.
Investors can sign up to Investor Meet Company for
free and add to meet Polarean Imaging plc
here. Investors who already follow Polarean
on the Investor Meet Company platform will automatically be
invited.
Whilst the Company may not be in a position to
answer every question it receives, it will address the most
prominent within the confines of information already disclosed to
the market through regulatory notifications. A recording of the
presentation will be available on the Investor Meet Company
platform afterwards.
Enquiries:
|
Polarean
Imaging plc
|
www.polarean.com / www.polarean-ir.com
|
|
Christopher von Jako, Ph.D., Chief
Executive Officer
Charles Osborne, Chief Financial
Officer
|
Via Walbrook
PR
|
|
Stifel (NOMAD and Sole Corporate Broker)
|
+44 (0)20
7710 7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Walbrook PR
|
Tel: +44
(0)20 7933 8780 or polarean@walbrookpr.com
|
|
Anna Dunphy / Phillip
Marriage
|
Mob: +44 (0)7876 741
001 / +44 (0)7867 984 082
|
|
|
|
|
| |
About Polarean
Polarean is a revenue-generating
medical imaging technology company revolutionising pulmonary
medicine through direct visualisation of lung function by
introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern
solutions to accurately assess lung function. The Company strives
to optimise lung health and prevent avoidable loss by illuminating
hidden disease, addressing the global unmet medical needs of more
than 500 million patients worldwide suffering from chronic
respiratory disease. Polarean is a leader in the field of
hyperpolarisation science and has successfully developed the first
and only hyperpolarised Xenon MRI inhaled contrast agent,
XENOVIEW™, which is now FDA-approved in the United States. Polarean
is dedicated to researching, developing, and commercialising
innovative imaging solutions with its non-invasive and
radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary
Xenon gas blend, gas hyperpolarisation system, as well as software
and accessories, facilitating fully integrated modern respiratory
imaging operations. Founded in 2012, with offices in Durham, NC,
and London, United Kingdom, Polarean is committed to increasing
global awareness of and broad access to its XENOVIEW MRI technology
platform. For the latest news and information about Polarean,
please visit www.polarean.com.
